The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

Founded Year



Unattributed | Alive

Total Raised


Last Raised

$2.54M | 9 mos ago

About Laurent Pharmaceuticals

Laurent Pharmaceuticals is a clinical stage company focusing on rare inflammatory diseases. Laurent's drug candidate, LAU-7b, is a Phase 2 ready oral drug addressing the compromised immune-inflammatory response in cystic fibrosis, a critical but still unaddressed pathogenic pathway causing pulmonary insufficiency in patients with CF.

Laurent Pharmaceuticals Headquarter Location

1010 Sherbrooke St West, Suite 2401

Montreal, Quebec, H3A 2R7,



Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Laurent Pharmaceuticals

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Laurent Pharmaceuticals is included in 1 Expert Collection, including Biopharma Tech.


Biopharma Tech

15,535 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Laurent Pharmaceuticals Patents

Laurent Pharmaceuticals has filed 2 patents.

The 3 most popular patent topics include:

  • Dosage forms
  • Experimental cancer drugs
  • Intracellular receptors
patents chart

Application Date

Grant Date


Related Topics




Transcription factors, Experimental cancer drugs, Phenols, Intracellular receptors, Dosage forms


Application Date


Grant Date



Related Topics

Transcription factors, Experimental cancer drugs, Phenols, Intracellular receptors, Dosage forms



Latest Laurent Pharmaceuticals News

Laurent Pharmaceuticals Starts Phase 3 Study With Once-a-Day Oral COVID-19 Antiviral Treatment Candidate in Hospitalized Moderate-to-Severe Patients

Feb 15, 2022

Following the positive outcome of a meeting with the FDA, a first patient was recruited in the Phase 3 expansion of the RESOLUTION study with LAU-7b in hospitalized moderate-to-severe COVID-19 patients Results from the RESOLUTION Phase 2 pilot portion showed 100% reduction in the risk of progression to mechanical ventilation and death in the LAU-7b-treated moderate-to-severe patients, relative to placebo LAU-7b is a broadly effective, once-a-day, oral COVID-19 antiviral candidate that addresses the gap in COVID-19 treatments between early infection and critical COVID-19 disease February 15, 2022 08:00 AM Eastern Standard Time MONTREAL--( BUSINESS WIRE )--Laurent Pharmaceuticals Inc. (the “Company”), a clinical-stage pharmaceutical company, today announced that Luminis Health Research Institute in Annapolis MD, USA, has dosed the first patient in the Phase 3 expansion of the RESOLUTION Phase 2/3 clinical trial evaluating the efficacy of the novel COVID-19 oral antiviral LAU-7b in hospitalized moderate-to-severe patients at high risk of developing lung complications. This Phase 3 confirmatory study was triggered following a successful meeting with the FDA, which also provided recommendations on the regulatory path to Emergency Use Authorization (EUA). LAU-7b is a next-generation COVID-19 oral antiviral that works by stopping the virus access to host cell membrane lipids needed for its entry and replication, a mechanism common to all lipid-enveloped viruses. Because it acts on the host rather than the virus, and also has inflammation-controlling properties, LAU-7b has broad applicability from early infection to severe disease, at-home or in hospital. “We are excited to reach the Phase 3 development milestone and the positive feedback received from the FDA, confirming the progress made so far with our LAU-7b program in COVID-19. There is still an important treatment gap for moderate-to-severe COVID-19 patients, the population most at-risk of progressing to respiratory failure,” said Radu Pislariu, MD, President and CEO of Laurent Pharmaceuticals. Jean-Marie Houle, VP Clinical Development, commented: “We are delighted to see our Phase 3 pivotal trial underway with clinical sites being swiftly activated in the USA and Canada. Existing COVID-19 oral antivirals typically target the virus’s biological machinery, which can be eluded by mutations, and are effective only if taken within 5 days of symptoms onset, during the virus proliferation stage. LAU-7b has the potential to become the next generation pan-coronavirus oral pill, so we will never be caught off-guard again by this virus.” “We now have multiple treatment options for early stage COVID-19, to prevent hospitalization, and a number of drugs to suppress hyperinflammation when a patient reaches critical stage, but not much specifically addressing hospitalized patients with moderate-to-severe COVID-19 to prevent their progression to invasive ventilatory support,” said Dr Barry Meisenberg, MD, a clinical investigator in the RESOLUTION trial. “Preventing ICU overload in this common subset of hospitalized patients is at core of our fight every time we face a new COVID-19 wave, as we try not only to protect the patients from life-threatening complications but also the healthcare system from a new crisis,” added Dr Meisenberg, who is also the chair of the Department of Medicine and medical director of the Research Institute at Luminis Health (formerly Anne Arundel Medical Center) in Annapolis MD, USA. About LAU-7b LAU-7b is developed as a broadly effective oral COVID-19 therapeutic targeting host cells membrane lipids to exert dual antiviral and inflammation-controlling activity. SARS-CoV-2 must reprogram host cellular lipid metabolism to favor its entry and replication, a mechanism shared by all lipid-enveloped viruses. Fenretinide, the active ingredient in LAU-7b, works by decreasing host cell membrane lipids fluidity and inhibiting de-novo cell lipogenesis. Because it acts on the host rather than the virus, LAU-7b has potential for broad-spectrum antiviral activity regardless of mutations, as already demonstrated in vitro on multiple SARS-CoV-2 variants (including Delta and Gamma) and the MERS-CoV. Fenretinide was also shown to trigger certain membrane phospholipids metabolic pathways involved in the resolution phase of inflammation, a natural mechanism that keeps the inflammatory response under control without inducing immune-suppression (a “pro-resolving” effect). About RESOLUTION Phase 2/3 clinical trial RESOLUTION is a placebo-controlled Phase 2/3 study of oral LAU-7b, administered once-a-day for 14 days on top of standard of care, in hospitalized COVID-19 patients at risk of developing pulmonary complications. Results from RESOLUTION Phase 2 pilot portion showed 100% reduction in the risk of progression to mechanical ventilation and death in LAU-7b-treated hospitalized moderate-to-severe COVID-19 patients, relative to placebo. None of the 76 patients on LAU-7b required mechanical ventilation and none died, while 5 out of 72 patients on placebo progressed to mechanical ventilation (6.9% difference, p=0.025), and 4 patients died (5.6% difference, p=0.053). LAU-7b group also showed an increase of 6.9% (p=0.055) in the proportion of patients alive and free of respiratory failure at Day 29, versus placebo. Both study arms were highly comparable in terms of mean age, number of comorbidities and concomitant medications. Patients on LAU-7b tended to recover more rapidly and leave hospital faster. LAU-7b was well-tolerated, with safety comparable to placebo. Following the positive results in the Phase 2 pilot study, the confirmatory Phase 3 portion was triggered, focusing on moderate-to-severe COVID-19 and using the “Proportion of patients requiring mechanical ventilation and/or death by Day 60” as the primary efficacy endpoint. More details about the RESOLUTION study can be found on , using Identifier NCT04417257. About Laurent Pharmaceuticals Laurent Pharmaceuticals is a clinical stage biotech company focusing on the modulation of cell membrane lipids for addressing life-threatening diseases. The company’s lead drug candidate, LAU-7b, is a proprietary oral formulation of fenretinide, an atypical retinoid with a well-documented safety profile established in more than 3,000 patients. Existing data suggest that low-dose fenretinide has the potential to modulate certain membrane lipids and exerts antiviral, inflammatory-controlling, and antifibrotic properties. LAU-7b is currently being evaluated as a potential therapeutic for COVID-19 and Cystic Fibrosis. For more information, please visit . Contacts

Laurent Pharmaceuticals Web Traffic

Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Laurent Pharmaceuticals Rank

  • When was Laurent Pharmaceuticals founded?

    Laurent Pharmaceuticals was founded in 2012.

  • Where is Laurent Pharmaceuticals's headquarters?

    Laurent Pharmaceuticals's headquarters is located at 1010 Sherbrooke St West, Suite 2401, Montreal.

  • What is Laurent Pharmaceuticals's latest funding round?

    Laurent Pharmaceuticals's latest funding round is Unattributed.

  • How much did Laurent Pharmaceuticals raise?

    Laurent Pharmaceuticals raised a total of $14.46M.

  • Who are the investors of Laurent Pharmaceuticals?

    Investors of Laurent Pharmaceuticals include National Research Council Canada, Government of Quebec, Cystic Fibrosis Foundation, Keiretsu Forum Mid-Atlantic, Aligo Innovation and 6 more.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.